[¹⁸F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma].
BACKGROUND
¹⁸F-FDG PET has been shown to be highly accurate for recurrent and metastatic disease as well as in restaging. The carcinoembryonic antigen (CEA) can be used as a marker of prognosis and recurrence.


OBJECTIVE
To evaluate the association between the presence of lesions detected with 18F-FDG PET/CT and CEA values in patients with colorectal carcinoma.


METHODS
We reviewed the records of 2,051 patients who underwent PET/CT to identify all the patients with colorectal carcinoma and previous CEA.


RESULTS
We included a total of 101 patients, 51 women and 50 men, with an average age of 60.21 years. The clinical stage that prevailed was ECIIA, with moderately differentiated adenocarcinoma histology (88.12%). There was agreement between the elevation of CEA and lesions detected by PET/CT in 73.9%. From the patients with normal values of CEA, in 42% the PET/CT study was positive for tumoral recurrence or metastases.


CONCLUSIONS
Our study revealed that 18F-FDG PET/CT can provided additional information in up to 42% of patients with normal ranges of carcinoembryonic antigen, detecting early recurrence or metastases.
Unidad pet/ct Ciclotrón, Universidad Nacional Autónoma de México, México, D.F.
Oliva
O
Granados Rangel
Unidad pet/ct Ciclotrón, Universidad Nacional Autónoma de México, México, D.F.
Gisela
G
Estrada
Unidad pet/ct Ciclotrón, Universidad Nacional Autónoma de México, México, D.F.
Javier
J
Altamirano
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000379:methods*
D002272:Carcinoembryonic Antigen; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18